Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log in to HL Account

Myovant Sciences Ltd (MYOV) NPV

Sell:$21.78 Buy:$21.83 Change: $1.41 (5.82%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:$21.78
Buy:$21.83
Change: $1.41 (5.82%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:$21.78
Buy:$21.83
Change: $1.41 (5.82%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The Company is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility.

Contact details

Address:
Ste 1 3rd Fl, 11/12 St. James's Square
LONDON
SW1Y 4LB
United Kingdom
Telephone:
+44 (20) 74003347
Website:
myovant.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MYOV
ISIN:
BMG637AM1024
Market cap:
$2.07 billion
Shares in issue:
90.80 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
Bermuda
Currency:
US dollar
Indices:
n/a

Key personnel

  • Myrtle Potter
    Chairman of the Board
  • David Marek
    Principal Executive Officer, Director
  • Frank Karbe
    Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
  • Matthew Lang
    General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
  • Adele Gulfo
    Director, Interim Chief Commercial Officer
  • Juan Camilo Arjona Ferreira
    Chief Commercial Officer - Myovant Sciences, Inc

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.